Class 4 Medicines Defect Notification: Chloramphenicol 1% w/w Eye Ointment, Blumont Pharma Limited, EL(25)A/20
Blumont Pharma Limited has informed the MHRA of an error with the European Article Number (EAN) barcode on the cartons of the batch of Chloramphenicol 1% w/w Eye Ointment (POM version only) in the below table.
DMRC Number: DMRC-35465724
Company name: Blumont Pharma Limited
Product description: Chloramphenicol 1% w/w Eye Ointment. PL: 31103/0021
SNOMED code: 42186711000001106
Details of the affected batch:
| Batch No. | Expiry Date | Pack Size | First Distributed |
| C0233 | 03/2029 | 4g tube | 25.04.2025 |
Active ingredient: chloramphenicol
Brief description of problem:
Blumont Pharma Limited has informed the MHRA of an error with the European Article Number (EAN) barcode on the cartons of the batch of Chloramphenicol 1% w/w Eye Ointment (POM version only) in the above table. The EAN for Chloramphenicol 0.5% eye drops 10ml (POM) has been included in error on the one batch of Chloramphenicol 1% w/w Eye Ointment (POM). The quality of the medicine is not impacted by the labelling defect.
Advice to Healthcare Professionals:
Healthcare professionals and recipients of this notification are advised not to use these batches of medicine in robotic or automated dispensing or stocking systems and to carry out manual dispensing and stocking, as appropriate.
Blumont Pharma Limited have confirmed that the defect is limited to the one batch of product in the above table.
Product quality of the Chloramphenicol 1% w/w Eye Ointment (POM) is not impacted by this issue; the barcode on the defective packs will identify Chloramphenicol 0.5% eye drops 10ml (POM), having the same active ingredient, same indication (Bacterial conjunctivitis) and the same duration of use, therefore the affected batches are not being recalled.
Advice to Patients:
No action is needed from patients, continue to take this medication as prescribed. The issue is related to the wrong barcode on the cartons of the listed batch of Chloramphenicol 1% w/w Eye Ointment (POM) and will be controlled by the healthcare professional’s prescribing/dispensing the medication. The quality of the medication is not affected.
Patients who experience adverse reactions or have any questions about their medication should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.
Company contacts for further information:
For medical information enquiries please email info@blumontpharma.com, or telephone 01476978568
For stock control enquiries please email manoj@blumontpharma.com, or telephone 01476978568
To access the full recall: